HUANG, Lianfeng,ZOU, Daozhong,NAGY, Mark A.,HILGRAF, Robert,LI, Ying,BOERSEN, Nathan Andrew,FERRETTI, Antonio Christian,KOTHARE, Mohit Atul,BEAUCHAMPS, Marie Georges,YONG, Kelvin Hin-yeong,XU, JEAN,MU
申请号：
PE2016001300
公开号：
PE20161437A1
申请日:
2015.01.29
申请国别(地区):
PE
年份:
2017
代理人:
摘要：
It refers to crystal compound 2 - (TER butilamino) - 4 - (1R, 3R, 4R) - 3-hydroxi-4-methylcyclohexamin) - pirimidin-5-carboxamida de form 1, which is characterized by X-ray powder diffraction characteristics, including 10.55, 13.61 and 19.84 of 2 (TetA) angle, It is a dynamic inhibitor of JNK1 or jnk2, which is useful in the treatment of pulmonary fibrosis and systemic sclerosis. It also refers to a treatment method and a method for preparing intermediate compounds of formula 4 and 3, wherein R1 and R2 are C1-C8 tar or substituted or unreplaced cyclopentyl tar.Se refiere al compuesto cristalino 2-(ter-butilamino)-4-(1R,3R,4R)-3-hidroxi-4-metilciclohexilamino)-pirimidin-5-carboxamida de formula 1 caracterizado por poseer un patron de difraccion en polvo por rayos X que comprende picos con angulos de 2(teta) de: 10.55, 13.61 y 19.84, el cual es un inhibidor de cinasas JNK1 o JNK2 y es util en el tratamiento de fibrosis pulmonar intersticial, esclerosis sistematica, entre otros. Tambien se refiere a un metodo de tratamiento y a un metodo de preparacion de los compuestos intermediarios de formula iv y iii, donde: R1 y R2 son alquilo C1-C8 o cicloalquilo sustituido o no sustituido
